ישראל - עברית - Ministry of Health

inovamed ltd - emtricitabine; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - emtricitabine; tenofovir disoproxil as phosphate - טבליות מצופות פילם - tenofovir disoproxil as phosphate 245 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - טבליות מצופות פילם - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme